Suzette Delaloge - Concepedia

Author

Suzette Delaloge

Also Known As

Delaloge Suzette, Delaloge, S., Delaloge, Suzette, G Pentheroudakis, Lise Bosquet, Meric-Bernstam, Funda, S Delaloge, S. Delaloge, SUZETTE DELALOGE, Suzette Delaloge

822

Publications

36.1K

Citations

H-Index

170

Concepts

All Affiliations

Institut Gustave Roussy Inserm Institut Curie Université Paris Cité Centre Georges François Leclerc

About

Suzette Delaloge is an author at Institut Gustave Roussy specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	50	118	13.2K
2	Health Sciences	24	43	3.5K
3	Engineering	10	10	765
4	Public Health	7	7	765
5	Nursing	6	6	634

Suzette Delaloge

243

Publications

30.3K

Citations

H-Index

Page 1

	Year	Citations
Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, New England Journal of Medicine	2017	3.1K
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Lionel Apétoh, François Ghiringhelli, Antoine Tesnière, Nature Medicine InflammationToll-like ReceptorsCancer ImmunosurveillanceImmune Cell DevelopmentInnate Immune System	2007	2.9K
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer Fátima Cardoso, Laura J. van’t Veer, Jan Bogaerts, New England Journal of Medicine	2016	2K
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy Antonella Sistigu, Takahiro Yamazaki, Erika Vacchelli, Nature Medicine Cancer ImmunosurveillanceMedicineImmunologyTumor ImmunityCancer Cell Biology	2014	1K
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer Mark E. Robson, Nadine Tung, Pierfranco Conté, Annals of Oncology	2019	725
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer David Miles, Joseph Gligorov, Fabrice André, Annals of Oncology	2021	689
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng, Journal of Clinical Oncology	2020	588
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Arlene Chan, Suzette Delaloge, Frankie A. Holmes, The Lancet Oncology Breast OncologyHealth SciencesMedicineClinical TrialsImmune Checkpoint Inhibitor	2016	551
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study Maria Vittoria Dieci, Carmen Criscitiello, Aïcha Goubar, Annals of Oncology Residual DiseaseBreast OncologyMedicinePrognostic ValueImmunology	2014	461

Page 1